Combined ethanol extract of Spermacoce radiata and Hypselodelphyspoggeana prevents renal damage and dyslipidemia in benign prostatic hyperplasia induced rats
الموضوعات : مجله گیاهان دارویی
رابرت اورکو
1
(گروه بیوشیمی، دانشکده علوم طبیعی، دانشگاه کشاورزی مایکل اوکپارا، ایالت ابیا، نیجریه)
پوول آنیام
2
(گروه بیوشیمی، دانشکده علوم طبیعی، دانشگاه کشاورزی مایکل اوکپارا، ایالت ابیا، نیجریه)
امانوئل اویو
3
(گروه بیوشیمی، دانشکده علوم طبیعی، دانشگاه کشاورزی مایکل اوکپارا، ایالت ابیا، نیجریه)
اوبینا آجا
4
(گروه بیوشیمی، دانشکده علوم طبیعی، دانشگاه کشاورزی مایکل اوکپارا، ایالت ابیا، نیجریه)
الکلمات المفتاحية: Lipid profile, Benign prostatic hyperplasia, Nephroprotective, Spermacoce radiata, Hypselodelphyspoggeana,
ملخص المقالة :
Background & Aim: A combined ethanol extract of Spermacoce radiata and Hypselodelphyspoggeana leaves are used for the treatment of benign prostatic hyperplasia, but there is no scientific data on its safety level and effects on vital organs and biochemical parameters. This study investigated the effects of a combined ethanol extract of Spermacoce radiata and Hypselodelphyspoggeana leaves (CESHL) on the lipid profile and kidney function of benign prostatic hyperplasia (BPH) induced rats.Experimental: A total of 21 rats were used for the acute toxicity study, while 30 were randomly distributed into five groups comprising six rats each (n = 6) for the BPH study. Group 1 served as normal control, while group 2 was BPH control that received 5 mg/kg of testosterone propionate/day for 28 consecutive days without treatment. Groups 3 – 5 received 5 mg/kg of testosterone propionate/day for 28 days but after an hour, they treated with 5 mg/kg of finasteride, 200 and 600mg/kg of CESHL/day, respectively, for 28 days.Results: The acute toxicity result of CESHL indicated no mortality or any sign of toxicity. Administration of the extract caused a significant reduction (p<0.05) of theprostate weight, triacylglycerol, cholesterol, low-density lipoprotein (LDL-C), urea and creatinine concentrations in the treated groups when compared to the BPH control. A significant increase (P<0.05) in High-Density Lipoprotein (HDL) concentration was observed in all treated groups when compared to the BPH control group. Histological outcomes of rats’ kidneys corroborated these findings.Recommended applications/industries: These results indicate that the combined extracts possess antilipidemic and nephroprotective effects, which might help in the management of complications that might arise during BPH.
Akbari, F., Azadbakht, M., Megha, K., Dashti, A., Vahedi, L., Nejad, A. B., Mahdizadeh, Z., Sarkami,
Albers, J.J.,Warmick, G.R. and Cheng, M.C. 1978. Determination of high-density lipoprotein (HDL) cholesterol. Lipids, 13:926-932.
Allain, C.C., Poon, L. S., Chan, C. S., Richmond, W. F. P. C., and Fu, P.C. 1974. Enzymatic determination of total serum cholesterol. Clinical Chemistry, 20(4): 470-475.
Asuk, A.A. and Ugwu, M.N. 2018. Nephrotoprotective effects of Vernonia amygdalina (bitter leaf) extract on benign prostatic hyperplasia in adult male rats.
International Journal of Biochemistry Research and Review, 22(4): 1-9
AUA Practice Guidelines Committee (2003). AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J. Urol., 170(2), 530–547.
Briganti, A., Capitanio, U., Suardi, N., Gallina, A., Salonia, A. and Bianchi, M. 2009. Benign prostatic hyperplasia and its aetiologies. European Urology Supplements, 8:865-871.
Chiong, E., Wong, A.F.W., Chan, Y.H., Chin, C.M. 2005. Review of clinical manifestations of biochemically advanced prostate cancer cases. Asian Journal of Surgery, 28(3): 202-206.
Dahle, S.E., Chokkalingam, A.P., Gao, Y.T., Deng, J., Stanczyk, F.Z.and Hsing, A.W. 2002. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. Journal of Urology, 168: 599-604.
Fawcett, J.K. and Scott, J. 1960. A rapid and precise method for the determination of urea. Journal of Clinical Pathology, 13(2): 156–159.
Fox, C.S., Larson, M.G. and Leip, E.P. 2004. Predictors of new-onset kidney disease in a community-based population. Journal of the American Medical Association, 291:844-850.
Friedelwald, W.T., Levy, R.I. and Fredrickson, D.S. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clinical Chemistry, 18(6): 499–502.
Henry, T.J. 1974. Clinical chemistry principles and techniques (2th ed.). New York: Harper and Row Publishers.
Ho, C.K. and Habib, F.K. 2011. Estrogen and androgen signalling in the pathogenesis of BPH. Nature Reviews Urology, 8(1):29-41.
Iscaife, A., Anjos, G., Barbosa, N. C., Nahas, W.C., Srougi, M. and Antunes, A. A. 2018. The role of bladder diverticula in the prevalence of acute urinary retention in patients with BPH who are candidates for surgery. International Brazilian Journal of Urology, 44(4): 765-770.
Lekili, M., Müezzinoğlu, T.,Uyanık, B. S. and Büyüksu, C. 2006. Serum lipid levels in benign prostatic hyperplasia. World Journal of Urology, 24(2): 210-213.
Lorke, D. 1983. A new approach to practical acute toxicity testing. Archives of Toxicology, 54(4): 275-287.
Minutoli, L., Rinaldi, M. and Marini, H. 2016. Apoptotic pathways linked to endocrine system as potential therapeutic targets for benign prostatic hyperplasia.International Journal of Molecular Sciences,17(8):1311. doi: 10.3390/ijms17081311.
NRC. 2011. Guide for the Care and Use of Laboratory Animals. Eighth Edition, Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, National Research Council (NRC), The National Academic Press, Washington DC, USA.
Parsons, J. K., Bergstrom, J. and Barrett‐Connor, E. 2008. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community‐dwelling men. British Journal Urology International, 101(3): 313-318.
Reshma, K., Kuthethur, S., Manjerekar, P. and Gopal, M. 2014. Evaluation of biochemical markers of renal dysfunction in prostate disorders and healthy controls. International Journal of Advanced Biochemistry Research, 5(9): 415-417.
Serhan, C.N. 2005. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukotrienes and Essential Fatty Acids, 73(3-4): 141-162.
Shin, I.S., Lee, M.Y., H.A, H.K., Seo, C.S. and Shin, H.K. 2012. Inhibitory effect of Yukmijihwang-tang: a traditional herbal formula against testosterone-induced benign prostatic hyperplasia in rats. BMC Complementary and Alternative Medicine, 12:48.
Traish, A.M., Hassani, J., Guay, A.T.,Zitzmann, M. and Hansen, M.L. 2011 Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. Journal of Sexual Medicine, 8: 872-884.
Uroko, R.I., Chukwu, C.N., Egba, S.I., Adamude, F.A. and Ajuzie, J.C. 2020. Combined ethanol extract of Funtumia africana and Abutilon mauritianium leaves improves the lipid profile and kidney function indices of benign prostatic hyperplasia in rats. Acta Scientiarum Polonorum, Technologia Alimentaria, 19(4): 395-404.
VeereshBabu, S., Veeresh, B., Patil, A.A. and Warke, Y.B. 2010.Combination of lauric acid and myristic acid prevent testosterone-induced prostatic hyperplasia in rats. European Journal of Pharmacology, 626 (2-3): 262-265.
Vinayak, M., Chandrashekhar, K. and Shishir, M. (2013). Pharmacological activities of Spermacocehispida Linn: A review. International Journal of Research in Ayurveda and Pharmacy, 4:18‑22.
Weinstein, S.J., Mackrain, K., Stolzenberg-Solomon, R.Z., Selhub, J., Virtamo, J. and Albanes, D. 2009. Serum creatinine and prostate cancer risk in a prospective study. Cancer Epidemiology, Biomarkers and Prevention, 18(10): 2643-2649.
Zhang, D.W., Garuti, R., Tang, W.J., Cohen, J.C., Hobbs, H.H. 2008. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proceedings of the National Academy of Sciences, 105(35): 13045-13050.
